J B Chemicals & Pharmaceuticals Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kywz42u3mq8ge9x14igofiex.pdf

Key Takeaways


Domestic Formulations: The Growth Engine

Kunal Khanna: "The slowdown is attributed to a few things which are not completely volume based. There have been big molecules and big brands which have been subject to price pressure which has led to a slowdown in the recent past. With respect to offtake of the molecules, patient adoption, or the compliance rates, systemically there is nothing really changing in the market."

Azmarda & the LOE Playbook

Kunal Khanna: "When we actually looked at this acquisition, we were very certain that there is going to be price erosion in the market. And we were quite prepared in terms of at what price we will be positioning our product... The scenario for us has not changed from what we initially envisaged in terms of how the market will shape up."

CDMO: The 20% Aspiration

Nikhil Chopra: "This business today is contributing 12% to our revenue. Going ahead probably 3 years from here, this business should contribute 20% of our revenue."

International Business: Mixed Geographies, Steady Growth

Nikhil Chopra: "What has been spoken in the world of U.S. business is we are a very small fish in a big point. So, we conceptually are working in accord to our strengths in terms of the products that we manufacture based on the technology backup that we have got, be it extended release, modified release."

Margins: The Recovery Thesis

Kunal Khanna: "And with the local sourcing of Azmarda already being activated, we see our gross margin profile inching upwards towards 64% and northwards moving ahead."

Portfolio & Productivity Levers


Guidance & Commitments

CommitmentSpecificsTimeline
Domestic growthMarket-beating performance, close to mid-teen growthOngoing
International growthClose to low double-digit growthOngoing
Gross margin recoveryInch toward 64% and northwards; Q4 in current range, build from Q1 onwardQ1 FY24 and beyond
EBITDA marginUpward from current standing; endeavor to improve next year vs this yearFY24
Chronic contributionImprove to close to 60% of India business from ~50%Short to midterm
CDMO revenue contributionReach 20% of total revenue from 12% currently3 years
CDMO new lozenge productsProof-of-concept launches in sleep disorders, motion sickness, oral thrush8 to 12 months
ROW BGx launchesProgressive portfolio launches in Sub-Sahara Africa, Latin America, Southeast Asia, Middle EastH2 next year
U.S. ANDA commercialization3 recent filings commercially available12 to 18 months
Cost synergiesMore benefits from acquired portfolio integrationFY24

Key Metrics

MetricQ3 FY23
Revenue₹793 cr, +32% YoY
Domestic revenue₹407 cr, +42% YoY
Organic domestic growthMid-teens YoY
International revenue₹385 cr, +23% YoY
International revenue constant currency growth17% to 18% YoY
Gross margin62.3%, vs 65% in FY22 and close to last quarter
Operating EBITDA (before ESOP)₹193 cr, +26% YoY
Operating EBITDA margin24.3%, vs 25.5% in Q3 FY22
Profit after tax₹106 cr, +26% YoY
CDMO revenue₹100 cr, +92% YoY
CDMO revenue contribution12% of total revenue
New product contribution to domestic businessClose to 5%, up from 1.5% in Oct 2020
Domestic volume growth4% to 5%
Domestic price growthClose to 7% to 8%
Chronic contribution to India businessClose to 50%
NLEM portfolio exposureCloser to 12% to 13%
Total MR strengthClose to 2,500
Company average MR productivityClose to ₹0.65 cr per MR per year
Net debt₹571 cr debt, ₹142 cr cash and investments
Blended cost of debtCloser to 8.1% to 8.2%
Interim dividend₹8.5 per share